What does high quality, trustworthy V1C look like? Explore the IMPACT Core Competencies framework to discover what good V1C looks like and how to get there.
Core Competency: Effectiveness
Produces outcomes that are valuable to key stakeholders
- Evidence of clinical outcomes
- Evidence of economic returns
- Satisfactory patient experience
- Evidence of sustained patient engagement
- Satisfactory provider experience
Effectiveness is a defining strength of high quality, trustworthy V1C. Effectiveness measures an organization’s ability to deliver valuable benefits to key stakeholders, including clinical outcomes, economic returns, patient and workforce experience beyond conventional care delivery models.
V1C providers that can provide convincing evidence of effectiveness gain patients’ trust, attract and retain the workforce, and gain additional access to patients through health plan networks, employers, and partnerships with new and traditional health systems.
Evidence required depends on company experience and stakeholder perspective: The breadth and depth of evidence available naturally vary depending on the maturity and experience of the platform: the most promising earliest stage V1C solutions will have clear logic supporting simulation models. In contrast, established providers representing the best-in-class solutions will have published data generated from robust, well-controlled clinical studies in representative populations and appropriately structured economic analyses.
Choose a stakeholder to explore their perspective on effectiveness.
Patients value convenience, access, and customer service when choosing a V1C provider over traditional care. The extent to which care aligns with their unique preferences and abilities for when, how, and where to receive care is an essential differentiator for V1C.
Maturity: Nascent
V1C delivery models have the potential to produce clinical outcomes equivalent to or exceeding those available through conventional care. However, there is still wide variability in the amount and types of data and performance measures reported by V1C providers to substantiate claims and in the evidence required by partners. Leading V1C providers view evidence generation as a continuous process, with data structured from the beginning to inform patient care, continuous product improvement, and clinical and economic performance insights.
What evidence do stakeholders want: Priority of Evidence
| Stakeholder | Engagement | Outcomes | Savings |
|---|---|---|---|
|
Enterprise Customers |
★ ★ ★ |
★ ★ ★ |
★ ★ ★ |
|
Health Plans / PBMs |
★ ★ ★ |
★ ★ ★ |
★ ★ ★ |
|
Partners / Consultants |
★ ★ ★ |
★ ★ ★ |
★ ★ ★ |
|
VCs / Funders |
★ ★ ★ |
★ ★ ★ |
★ ★ ★ |
*Source: Omada Health, IMPACT Project team
Collects outcomes data from the earliest stages to support ongoing evidence generation for market access and continuous clinical improvement.
Measures outcomes relevant to the condition and meaningful to patients; where available reports and ‘gold-standard’ measures are defined by medical and clinical standards societies:
- E.g., Reduction in real HbA1c is an outcome measure endorsed by the American Diabetes Association (ADA) for diabetes management programs
- Demonstrates that outcome improvements for chronic conditions are sustainable
Conducts studies with populations, comparison groups, and study methodologies that are:
- Representative of real-world practice and target market
- Ability to stratify outcomes by equity measures such as social determinants of health (SDOH)
- Selects study designs that:
- Reduce/eliminate study bias using scientific best practices, e.g., controls and randomization to attribute a V1C intervention to outcomes improvements; pursues publication in peer-reviewed journals
- Are appropriate for the research questions: e.g., ‘Gold standard’ randomized clinical trials (RCT) may not be appropriate or feasible for early stage innovations or to assess performance in real-world practice settings but may be required to attribute clinical and economic outcomes to the solution. However, retrospective data analysis and single-arm studies can support feasibility in a specific population.
The economic model works within the cost structure of potential buyers, with economic outcomes meeting or surpassing existing standards in the broader market.
- Early stage entities: Ability to demonstrate ROI and break-even points for potential partners using combinations of predicted outcomes and published cost estimates and real-world evidence
- Established entities: robust evidence available from claims analysis of net savings in total healthcare costs attributable to the intervention from well-controlled health economic studies (E.g., RCTs or pragmatic studies)
Reports high user satisfaction on standard industry metrics (e.g., Net Promoter Score (NPS), Star Ratings) in the top 80 percentile.
- Ability to measure patient activation
- Surveys the relevant number and breadth of users
- If applicable, demonstrated impact on Healthcare Effectiveness Data and Information Set (HEDIS) measures
- Track and report a variety of engagement measures, including enrollment but also active participation
- Understand the relationship between the type and rate of events or activities on their platform and clinically meaningful, patient-salient improvements in outcomes
- Monitor engagement over time, and leverage analytics to stratify and continuously personalize content and engagement tactics to individuals
Supports efficient V1C provider team workflows using technology to optimize collaboration in the digital environment and contribute at their highest level of training.
Provides evidence of high provider satisfaction both within the V1C entity and with partner providers.
